Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
autologous mononuclear stem cell (1 trial)
bortezomib (velcade) (1 trial)
lenalidomide (revlimid) (1 trial)
urea (1 trial)
rituximab (rituxan) (1 trial)
thalidomide (Thalomid) (1 trial)
Multiple Myeloma (Phase 3)
Neoplasms, Plasma Cell (Phase 3)
Waldenstrom Macroglobulinemia (Phase 2)
Trials (2 total)
Trial APIs (6 total)